Related by context. All words. (Click for frequent words.) 77 relapsing multiple sclerosis 73 beta 1a 73 Aflibercept 72 teriflunomide 72 AVONEX ® 71 Meets Primary Endpoint 71 Natalizumab 71 Safinamide 71 GW# [003] 71 Hsp# Inhibitor 71 recurrent glioblastoma multiforme 71 CYT# potent vascular disrupting 70 Phase 2b Clinical Trial 70 Teriflunomide 70 leukemia AML 70 immunomodulatory therapy 70 erlotinib Tarceva ® 70 orally inhaled migraine 70 PRT# 70 R lenalidomide 70 Relapsing Remitting Multiple Sclerosis 70 pomalidomide 70 forodesine 70 Bezielle 69 stage IIIB 69 nucleoside analog 69 relapsing remitting multiple sclerosis 69 CCX# B 69 dextromethorphan quinidine 69 Oral Fingolimod 69 PEGylated anti 69 ACTEMRA TM 69 PEGylated Fab fragment 69 elotuzumab 69 Antitumor Activity 69 oral prodrug 69 MKC# MT 69 diarrhea predominant irritable 69 sorafenib tablets 69 Pivotal Phase III 69 SPRYCEL ® 69 Pegloticase 69 lintuzumab SGN 69 dasatinib Sprycel ® 69 Myelodysplastic Syndrome MDS 69 visilizumab 68 INSPIRE Trial Phase III 68 Hormone Refractory Prostate Cancer 68 metastatic castration resistant 68 mapatumumab 68 JAK2 Inhibitor 68 Traficet EN 68 phase IIb clinical 68 Severe Sepsis 68 vidofludimus 68 Phase 2a Clinical Trial 68 MAGE A3 ASCI 68 tocilizumab 68 metastatic malignant 68 CTAP# Capsules 68 TNF Tumor Necrosis Factor 68 Copegus ® 68 FOLOTYN ® 68 alfa 2a 68 Tanespimycin 68 Myelofibrosis 68 cetuximab Erbitux R 68 ritonavir boosted 68 lumiliximab 68 Initiates Enrollment 68 Completes Patient Enrollment 68 II Clinical Trial 68 refractory chronic lymphocytic 68 selective modulator 68 hyperphenylalaninemia HPA due 68 docetaxel Taxotere ® 68 Interferon alpha 68 First Patient Dosed 68 adalimumab Humira 68 HuMax EGFr 68 Novel Oral 68 Cardiotoxicity 68 Pivotal Phase 68 Tarceva TM 68 prokinetic agent 68 CIMZIA TM 68 YONDELIS 68 pan HDAC inhibitor 68 refractory gout 68 Cimzia TM 68 Pharmacokinetics PK 68 nab paclitaxel 67 Diabetic Macular Edema DME 67 Personalized Immunotherapy 67 myelodysplastic myeloproliferative diseases 67 Romidepsin 67 antibody MAb 67 novel VDA molecule 67 TO AVOID PREGNANCY WHILE 67 Adalimumab 67 Phase IIb Clinical Trial 67 6R BH4 67 Ocrelizumab 67 Phase 2b Trial 67 mertansine 67 IMA# 67 Advanced Renal Cell 67 Previously Treated 67 Ozarelix 67 Antiviral Activity 67 Nilotinib 67 Pazopanib 67 dasatinib Sprycel 67 Adjuvant Treatment 67 histone deacetylase HDAC inhibitor 67 Randomized Phase 67 Panzem R 67 Interferon beta 1a 67 Cutaneous T 67 Pegasys ® 67 Plicera 67 PEG IFN 67 idiopathic thrombocytopenic purpura ITP 67 oncolytic virus therapies 67 CIMZIA TM certolizumab pegol 67 INCB# [003] 67 Fibrillex TM 67 VEGF inhibitors 67 fosbretabulin 67 Epratuzumab 67 PEGINTRON TM 67 relapsed refractory multiple myeloma 67 CIMZIA ™ 67 relapsing remitting MS RRMS 67 inhibitor RG# 67 ALN TTR 67 AAG geldanamycin analog 67 Cloretazine 67 ularitide 67 neratinib 67 ribavirin Copegus ® 67 somatostatin analog 67 PNP inhibitor 67 Initiate Phase 67 imatinib Gleevec ® 67 relapsed MM 67 2 methoxyestradiol 67 riociguat 67 Zenvia ™ 67 trastuzumab Herceptin R 67 Vidofludimus 67 GOUT 67 Phase IIb Trial 67 BARACLUDE ® 67 post herpetic neuralgia PHN 67 thalidomide Thalomid 67 Pemetrexed 67 Glufosfamide 67 sunitinib Sutent ® 67 Eculizumab 67 ORENCIA ® 67 Triapine R 67 phase IIa clinical 67 Temsirolimus 67 mu opioid receptor antagonist 67 superficial bladder cancer 67 STRIDE PD 67 Capecitabine 67 rilonacept 67 Patients Treated With 67 baminercept 66 plasma kallikrein inhibitor 66 virus HCV protease inhibitor 66 receptor tyrosine kinase inhibitor 66 Telbivudine 66 albiglutide 66 Initiates Clinical Trial 66 cell lymphoma CTCL 66 ZOLINZA 66 XL# XL# 66 MDS MPD 66 Neoadjuvant 66 oral FTY# 66 Benign Prostatic Hyperplasia 66 demonstrated antitumor activity 66 Dasatinib 66 Glatiramer Acetate 66 Certolizumab 66 systemically administered 66 Long Term Efficacy 66 Peginterferon 66 Decitabine 66 velafermin 66 Aliskiren 66 Prospective Randomized 66 evaluating tivozanib 66 MGd 66 Chronic Hepatitis C 66 mitoxantrone plus 66 mRCC 66 pertuzumab 66 CR# vcMMAE 66 Systemic Sclerosis 66 Ambrisentan 66 Pooled Analysis 66 HCV SPRINT 66 PDX pralatrexate 66 Enzyme Replacement Therapy 66 bendamustine 66 RECORD1 66 STELARA TM 66 Paraplatin ® 66 docetaxel Taxotere R 66 Romiplostim 66 Zorbtive TM 66 Doxil ® 66 Sapacitabine 66 Amrubicin 66 fluvastatin 66 EDEMA3 66 sitaxsentan 66 CLARITY study 66 Archexin 66 vandetanib 66 HQK 66 RhuDex TM 66 Ranolazine 66 investigational hepatitis C 66 Tezampanel 66 oral ridaforolimus 66 RoACTEMRA 66 Annamycin 66 proteasome inhibitor 66 chronic eosinophilic leukemia 66 SinuNase TM 66 Monotherapy 66 Phase Ib Clinical Trial 66 Elotuzumab 66 primary hypercholesterolemia 66 TORISEL 66 cisplatin gemcitabine 66 HuMax CD4 66 Octreolin 66 Peginterferon alfa 2b 66 DOXIL 66 posaconazole 66 Successfully Completes Phase 66 mGluR5 negative 66 humanized interleukin 6 66 Refractory Angina 66 orally bioavailable 66 SYN# 66 PEG SN# 66 Omacetaxine 66 Telintra 66 PEGASYS ® 66 Panzem R NCD 66 Critical Limb Ischemia CLI 66 RRMS 66 LHRH antagonists 66 Receives Orphan Drug Designation 66 herpetic keratitis 66 LymphoStat B TM 66 sunitinib malate 66 investigational antiplatelet agent 66 Castration Resistant Prostate Cancer 66 corticosteroid dexamethasone 66 ADP receptor antagonist 66 Factor VIIa 66 complement inhibitor eculizumab 66 investigational humanized monoclonal antibody 66 Dose Ranging Study 66 unfractionated heparin UFH 66 R Saizen R 66 Initiated Phase 66 Toxicities 66 BCG refractory carcinoma 66 aripiprazole Abilify 66 Phase 2a Trial 66 R roscovitine 66 Rigel R# 66 thromboembolic events 66 Blinatumomab 66 Carfilzomib 66 axitinib 66 RhuDex ® 66 ® lenalidomide 66 investigational monoclonal antibody 66 Febuxostat 66 targeted radiotherapeutic 66 peripherally acting 66 Lubiprostone 66 invasive candidiasis 66 RRMS patients 66 Betaferon R 66 Interferon Beta 66 Cannabinor 66 Relapsing Multiple Sclerosis 66 JAK Inhibitor 66 mycophenolate mofetil 66 paclitaxel poliglumex 66 HMG CoA reductase inhibitors 66 PRTX 66 Vidaza azacitidine 66 APTIVUS r 66 peritumoral brain edema 66 acetonide FA 66 essential thrombocythemia ET 66 myopathy rhabdomyolysis 66 phase IIb trial 66 Brentuximab Vedotin SGN 66 AVASTIN 66 PKC# 66 MKC# MKC# PP 66 liposomal formulation 66 Clolar ® 66 ancrod 66 depsipeptide 65 Phase Ib clinical 65 Irinotecan 65 orally administered inhibitor 65 Alemtuzumab 65 KRN# 65 prucalopride 65 Metastatic Renal Cell Carcinoma 65 Daclizumab 65 Phase IIb clinical trials 65 IL# PE#QQR 65 TELINTRA 65 interferon gamma 1b 65 atacicept 65 Tyrima 65 hypercalcemia 65 castrate resistant prostate cancer 65 advanced hepatocellular carcinoma 65 multicenter Phase III 65 icatibant 65 Metastatic Prostate Cancer 65 IV NSCLC 65 Dual Opioid 65 phase III isavuconazole 65 Noxafil 65 Solazed TM 65 bevacizumab Avastin ® 65 MT# MEDI 65 Torisel 65 formerly LymphoStat B 65 Newly Diagnosed Multiple Myeloma 65 Ecallantide 65 Presents Preclinical Data 65 Trial Evaluating 65 LymphoStat B belimumab 65 mg kg BID 65 Completes Enrollment 65 catheter occlusion 65 Tyrosine Kinase Inhibitor 65 HuLuc# 65 Laquinimod 65 alemtuzumab Campath 65 huN# DM1 65 MabCampath 65 ALN HPN 65 familial amyloidotic polyneuropathy FAP 65 metastatic hormone refractory 65 LUX Lung 65 vapreotide acetate 65 rNAPc2 65 PSMA ADC 65 canakinumab 65 PXD# 65 lexidronam injection 65 Pulmonary Arterial Hypertension 65 phase IIIb 65 CEQ# 65 HIV HCV coinfected 65 PROVENGE sipuleucel T 65 bevacizumab Avastin R 65 sorafenib Nexavar 65 Phase Ib II 65 Combination REOLYSIN R 65 Pafuramidine 65 reslizumab 65 Phase III Clinical Trial 65 alvespimycin 65 Golimumab 65 OHR/AVR# 65 polycythemia vera essential thrombocythemia 65 thromboembolic complications 65 Diffuse Large B 65 leukemia CLL 65 Treatment Naive Patients 65 Unstable Angina 65 sapropterin dihydrochloride 65 Belimumab 65 Platinol ® 65 Phase IIIb clinical 65 Apixaban 65 HeFH 65 REMINYL ® 65 lead Aganocide compound 65 hypereosinophilic syndrome 65 Advanced Melanoma 65 Voreloxin 65 Rebif ® 65 dirucotide 65 glatiramer acetate 65 FASLODEX 65 AIR CF1 65 refractory multiple myeloma 65 HER2 positive metastatic breast 65 toenail onychomycosis 65 dirucotide MBP# 65 panitumumab Vectibix 65 nephrotoxicity 65 tanespimycin 65 developing Bicifadine serotonin 65 psoriatic arthritis PsA 65 Maribavir 65 Clinical Trial Results 65 efalizumab 65 ocrelizumab 65 octreotide acetate 65 MULTAQ 65 Complicated Skin 65 PDE4 inhibitor 65 Initiates Phase III 65 including eniluracil ADH 65 histone deacetylase inhibitor 65 arsenic trioxide injection 65 somatostatin analogue 65 HES CEL 65 atherothrombotic events 65 administered subcutaneously 65 galiximab 65 RELOVAIR ™ 65 NS#/#A protease 65 assessing T DM1 65 dyskinesia PD LID 65 phase IIb study 65 Pegylated Liposomal Doxorubicin 65 dose cohort 65 refractory NSCLC 65 nucleoside naive 65 brivaracetam 65 metaglidasen 65 urate lowering 65 Phase IIb trials 65 DAVANAT 65 active ankylosing spondylitis 65 Metastatic Melanoma 65 varespladib 65 Quinamed 65 Prolongs Survival 65 Syncria R 65 Pivotal Trial 65 HER2 overexpression 65 severe oral mucositis 65 diabetic neuropathic pain 65 Phase Ib study 65 SNT MC# 65 lenalidomide dexamethasone 65 INCB# [001] 65 Mitoxantrone 65 Metastatic Colorectal Cancer 65 IMiDs ® 65 sJIA 65 PegIFN 65 Microplasmin 65 vascular disrupting agent 65 cutaneous T 65 endothelin antagonists 65 LY# [003] 65 INS# [001] 65 ara C 65 Anti Tumor Activity 65 xanthine oxidase inhibitor 65 cilengitide 65 cMET 65 TBC# 65 Chronic Lymphocytic Leukemia 65 Anthracycline 65 antiviral efficacy 65 IIIa inhibitor 65 recurrent GBM 65 Exelixis compounds 65 Dacogen injection 65 CRMD# 65 Mycophenolate Mofetil 65 generation purine nucleoside 65 FDA APPROVES 65 Renal Cell Carcinoma 65 biologic DMARD 65 lymphoma CTCL 65 desvenlafaxine succinate 65 hyperplasia BPH 65 gefitinib Iressa 65 INTEGRILIN R 65 Symadex 65 TACI Ig 65 cetuximab Erbitux ® 65 unresectable stage 65 Initiates Phase II 65 Aplidin R 65 Entereg R 65 IMiDs ® compound 65 plus COPEGUS 65 pediatric Crohn disease 65 XL# anticancer compounds 65 Sandostatin R 65 Chronic Lymphocytic Leukemia CLL 65 gemcitabine Gemzar ® 65 temsirolimus 65 Simulect 65 REMICADE ® 65 HCV RESPOND 2 65 transthyretin TTR mediated amyloidosis 65 Navelbine ® 65 romidepsin 64 invasive aspergillosis 64 VELCADE melphalan 64 Hepatocellular Carcinoma 64 Acute Heart Failure 64 sodium thiosulfate STS 64 PD LID 64 multicenter Phase II 64 Fludara ® 64 etanercept Enbrel 64 Synta Announces 64 melphalan prednisone 64 Bronchiectasis 64 trastuzumab Herceptin ® 64 adult chronic ITP 64 Plaque Psoriasis 64 Tiotropium 64 cannabinor 64 non splenectomized 64 Pyridorin 64 DEB# 64 HCV Protease Inhibitor 64 Copegus ribavirin 64 dexpramipexole 64 Allovectin 7 R 64 acute peripheral arterial 64 First Patient Enrolled 64 Hodgkin lymphoma HL 64 Talabostat 64 Angiotensin Converting Enzyme 64 candesartan cilexetil 64 HCD# [002] 64 decitabine 64 methylnaltrexone bromide 64 Clostridium difficile Infection 64 Diabetic Macular Edema 64 Phase III Trial 64 metastatic neuroendocrine tumors 64 ENMD # 64 Cethromycin 64 Acute Ischemic Stroke 64 humanised monoclonal antibody 64 intravenous methylnaltrexone 64 EOquin TM phase 64 Methylnaltrexone 64 hoFH 64 AZILECT R 64 Reports Preclinical Data 64 Exherin TM 64 Dapagliflozin 64 Dalbavancin 64 tumor lysis syndrome 64 taxane resistant 64 oral vancomycin 64 mg QD 64 8mg/kg 64 DAPT 64 induce orthostatic hypotension 64 chemotherapy induced neutropenia 64 Preclinical Data 64 Anti VEGF 64 Aryplase 64 severe hypercholesterolemia 64 Kepivance 64 Fludarabine 64 Vandetanib 64 EURIDIS 64 weekly subcutaneous injections 64 DU #b 64 PANVAC VF 64 Fondaparinux 64 Phase #/#a trial 64 pan histone deacetylase 64 TRO# 64 posterior uveitis 64 hypoxia activated prodrug 64 Firazyr 64 alpha 2a 64 laquinimod 64 Luteinizing Hormone Releasing Hormone 64 PAOD 64 Seliciclib 64 Initiates Clinical 64 HGS ETR2 64 Kinoid 64 IFN beta 64 Bevacizumab 64 MyVax R 64 Oral Mucositis 64 alefacept 64 ruboxistaurin 64 PRN FDA Approves 64 Raptiva R 64 Patients Treated 64 TLK# 64 SAR# [002] 64 Placebo Controlled Trial 64 midstage clinical 64 Etanercept 64 Mg Uk 64 Tocilizumab 64 ILUVIEN ® 64 HBeAg negative 64 oral proteasome inhibitor 64 recurrent NSCLC 64 pegylated interferon alfa 2a 64 postoperative ileus POI 64 lupus nephritis 64 TMC# C# 64 AA Amyloidosis 64 CANCIDAS 64 beta interferons 64 FOLFOX6 chemotherapy regimen 64 ARCOXIA 64 steroid refractory ulcerative 64 Protease Inhibitor 64 Tumor Necrosis Factor 64 LUMINATE 64 GAMMAGARD 64 systemic juvenile idiopathic 64 eltrombopag 64 PTH analogue 64 Fulvestrant 64 myeloproliferative disorders 64 evaluating REVLIMID 64 pharmacokinetic PK study 64 volociximab 64 Xelox 64 pharmacokinetic interactions 64 GERD migraine headaches 64 Oral Compound 64 Achieves Primary Endpoint 64 ZACTIMA 64 acadesine 64 phase Ib 64 ribavirin RBV 64 Lupus Nephritis 64 Cetrorelix 64 COPD exacerbations 64 Panzem ® 64 Trastuzumab 64 thiazolidinedione TZD 64 Liprotamase 64 Ofatumumab 64 liposomal amphotericin B 64 Initiates Phase 2b 64 FOLFOX6 64 Phase III Clinical Trials 64 Alequel 64 Anti TNF 64 R sorafenib tablets 64 q#h 64 Heterozygous Familial Hypercholesterolemia 64 Bosutinib 64 myelofibrosis polycythemia vera 64 viral kinetics 64 PROMACTA 64 radiation sensitizer 64 Cell Lymphoma 64 painful diabetic neuropathy 64 atypical Hemolytic Uremic Syndrome 64 brand ciclesonide HFA 64 Chronic Myeloid Leukemia 64 adenosine injection 64 HDAC Inhibitor 64 refractory AML 64 Forodesine HCl 64 oral rivaroxaban 64 TG# [003] 64 Polymerase Inhibitor 64 direct thrombin inhibitors 64 imatinib therapy 64 Tigecycline 64 Efficacy Results 64 Pivotal Study 64 efficacy tolerability 64 oral cladribine 64 Campath alemtuzumab 64 Study Evaluating 64 Medoxomil 64 EVIZON TM 64 oral nucleoside analogue 64 Copegus R 64 TYZEKA 64 Presents Preclinical 64 RezularTM 64 budesonide foam 64 R#/MEM # 64 Phenoptin 64 LymphoStat B 64 Adjunctive Therapy 64 Epidermal Growth Factor Receptor 64 rFVIIa 64 intravesical instillation 64 Xeloda ® 64 Pimavanserin 64 sunitinib Sutent 64 EGFR HER2 64 ankylosing spondylitis AS 64 CCX# 64 BAY #-# 64 Phase #b/#a clinical 64 vinca alkaloid 64 rALLy clinical trial 64 Fidaxomicin 64 Adjuvant Therapy 64 uricase 64 Xanafide 64 BRIM2 64 Aviptadil 64 treatment naive genotype 64 antiangiogenic agent 64 occlusion PAO 64 HGS ETR1 mapatumumab 64 Immunotherapeutic 64 5 FU leucovorin 64 MEK inhibitor 64 renal toxicity 64 Non inferiority 64 TAXUS Stent 64 recurrent glioma 64 metastatic pancreatic 64 Pivotal Phase II 64 aplindore 64 Elagolix 64 CALGB # [002] 64 Hepatotoxicity 64 clopidogrel Plavix 64 mGluR5 NAM 64 ribavirin USP 64 certolizumab 64 5 Fluorouracil 64 Drug Candidate 64 Orally Active 64 BoNTA 64 PRE SURGE 64 registrational trial 64 Improved Survival 64 OMNARIS HFA 64 Demonstrates Significant 64 Solorel TM 64 Amgen Neulasta R 64 Tolvaptan 64 opioid induced constipation OIC 64 severe gastroparesis 64 oxaliplatin Eloxatin 64 Azacitidine 64 Kinase Inhibitor 64 tafamidis 64 vismodegib 64 HCV protease inhibitors 64 Stage IIB 64 erythematosus 64 TRANSFORMS 64 TYKERB 64 ACZ# 64 NATRECOR ® 64 leukemia ALL 64 Aptivus ® 64 Initiates Phase 64 non nucleoside HCV 64 Ceflatonin R 64 omacetaxine mepesuccinate 64 secondary hyperparathyroidism 64 virus HCV infection 64 adriamycin 64 tolerability pharmacokinetics 64 Vfend 64 alpha interferons 64 trastuzumab DM1 64 Gabapentin GR 64 micafungin 64 thetreatment 64 Vivecon 63 Boceprevir 63 dose escalation clinical 63 ZYBRESTAT fosbretabulin 63 ocular formulation 63 FOLPI 63 Lenalidomide 63 Atypical Hemolytic Uremic Syndrome 63 R# #mg BID 63 immunomodulatory agents 63 Refractory Hodgkin Lymphoma 63 Hedgehog Pathway Inhibitor 63 Investigational Treatment 63 Arranon 63 Bosentan 63 CRLX# 63 Nitazoxanide 63 metastatic colorectal carcinoma 63 novel oral anticoagulant 63 SCH # 63 Zenvia Phase III 63 metastatic renal cell carcinoma 63 CD# CEA 63 Bicifadine 63 Phase 1b trial 63 Campath ® 63 Is Well Tolerated 63 telomerase therapeutic 63 Randomized Double Blind Placebo 63 receiving prophylactic anticoagulation 63 delafloxacin 63 tigecycline 63 Bortezomib 63 Dementia Related Psychosis 63 NOXAFIL 63 pegylated liposomal doxorubicin 63 motesanib 63 Radezolid 63 Androxal TM 63 gastrointestinal stromal tumors GIST 63 mg TID 63 rheumatoid arthritis psoriatic arthritis 63 rufinamide 63 humanized anti 63 Angioedema 63 receptor inhibitor 63 Pirfenidone 63 delivers fluocinolone acetonide FA 63 refractory CTCL 63 Gleevec resistant 63 Degarelix 63 R#/MEM 63 Soft Tissue Sarcoma 63 BENLYSTA TM 63 clazosentan 63 Aurora Kinase 63 administered concomitantly 63 Navelbine 63 pediatric malignancies 63 Eluting Coronary Stent System 63 Ischemic 63 Clinical Trial Evaluating 63 relapsing MS 63 RAPTIVA 63 Neulasta ® 63 mg BID 63 IBS C 63 seliciclib CYC# 63 phase IIa 63 Relapsed Multiple Myeloma 63 APTIVUS 63 ISTODAX ® 63 irreversible inhibitor 63 Treatment Naïve 63 apoptosis inducer 63 Peginterferon Alfa 2a 63 IRX 2 63 vorinostat 63 intranasal formulation 63 Velcade bortezomib 63 rFIXFc 63 estramustine 63 gemcitabine carboplatin 63 Begins Dosing 63 paclitaxel cisplatin 63 FOLFOX chemotherapy 63 standard chemotherapy regimen 63 PROSTVAC VF 63 Azixa 63 chronic myocardial ischemia 63 INFERGEN 63 metastatic gastric 63 Randomized Phase II 63 Pivotal Clinical Trial 63 IgG1 monoclonal antibody 63 Zometa zoledronic acid 63 oral methylnaltrexone 63 BENICAR HCT 63 RAPAFLO R 63 JAK1 63 TEMSO 63 Progressive Multifocal Leukoencephalopathy 63 JAK2 inhibitor 63 ARIXTRA 63 CA4P 63 novel emulsion formulation 63 MERLIN TIMI 63 Randomized Study 63 Pertuzumab 63 liposome injection 63 edoxaban 63 Exelixis XL# 63 Diabetic Neuropathy 63 Exacerbation 63 multicenter Phase 63 SNT-MC#/idebenone 63 OvaRex R 63 Ovitrelle R Serostim 63 alpha 2b 63 ADHF 63 BAL# [002] 63 See CLINICAL PHARMACOLOGY 63 myeloproliferative diseases 63 relapsed multiple myeloma 63 anti leukemic 63 pimozide 63 Pharmacokinetic 63 rasagiline tablets 63 PsA 63 OncoVex 63 interferon beta 1a infertility 63 Evoltra ® 63 adalimumab 63 small molecule tyrosine 63 Akt inhibitor 63 Non Alcoholic Steatohepatitis 63 romiplostim 63 glatiramer 63 Azedra 63 JAK inhibitor 63 Mg Usa 63 Inhalation Aerosol 63 palifermin 63 Single Dose 63 Dose Escalation 63 ATACAND 63 randomized discontinuation trial 63 investigational protease inhibitor 63 XL# SAR# 63 either acutely decompensated 63 humanized monoclonal 63 molecular imaging radiopharmaceutical 63 autoantibody positive 63 Bucindolol 63 Gemzar ® 63 antiplatelet agent 63 registrational Phase 63 Phase III Pivotal 63 refractory CLL 63 evaluating picoplatin 63 NATRECOR R 63 analgesic efficacy 63 chronic myeloid 63 placebo controlled Phase 63 salmeterol fluticasone 63 primary immunodeficiency PI 63 novel histone deacetylase 63 Cimzia ® certolizumab pegol 63 investigational oral inhibitor 63 coadministration 63 antiarrhythmic drug 63 Albuferon TM 63 recurrent genital herpes 63 treatment naïve genotype 63 MYCAMINE 63 Certolizumab pegol 63 FUSILEV enhances 63 RANK Ligand inhibitor 63 sipuleucel T 63 mucosal healing 63 personalized immunotherapy 63 dexamethasone Decadron 63 plus gemcitabine 63 clevidipine 63 Controlled Trial 63 IN PATIENTS WITH 63 TNF antagonist 63 Well Tolerated 63 dose cohorts 63 unstable angina UA 63 randomized controlled Phase 63 Inhalation Solution 63 Heart Failure Patients 63 CMV disease 63 HCl Tablets 63 Afatinib 63 CB2 selective receptor agonist 63 glucocorticoid induced osteoporosis 63 anti muscarinic 63 uric acid lowering 63 kidney urologic 63 resistant hormone refractory 63 multicenter randomized placebo controlled 63 sapropterin dihydrochloride Tablets 63 RNAi Therapeutic 63 EXPAREL ™ 63 IMiDs 63 evaluating Actimmune 63 CML CP